EPINEPHrine IV Bags Recalled Due to Sterility Assurance Failure
Central Admixture Pharmacy Services, Inc. is recalling EPINEPHrine 8mg/250ml IV bags due to lack of sterility assurance and insufficient validation data for decontamination cycles. The recall affects 4,570 units distributed nationwide.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall involving potential sterility issues with injectable medication. No illnesses or injuries have been reported in the source material, but the hazard presents significant risk due to the nature of sterile injectable pharmaceuticals and the lack of proper sterilization validation data.
Plain-English summary
Central Admixture Pharmacy Services, Inc. is recalling EPINEPHrine 8mg/250ml IV bags (32 mcg/mL in dextrose 5%). The manufacturer, located in Phoenix, Arizona, is withdrawing approximately 4,570 units that were distributed nationwide.
The recall was initiated due to lack of assurance of sterility. The manufacturer lacks adequate validation data for decontamination cycles, which are essential to ensure the product's sterility.
Affected lots include multiple batch numbers with expiration dates ranging from July 16, 2023 through September 7, 2023 (NDC: 72196-7019-1).
Healthcare providers who have received these IV bags should not use them and should remove them from inventory. Healthcare providers or patients who believe they have been exposed to this product should consult their healthcare provider. Adverse events should be reported to the FDA's MedWatch program.
The recalled product
- Product
- EPINEPHrine 8mg/250ml added to dextrose 5%, 32 mcg/mL, IV Bag, Rx Only, Central Admixture Pharmacy Services, Inc., 2200 South 43rd Avenue, Phoenix, AZ 85043, NDC: 72196-7019-1.
- Manufacturer
- Central Admixture Pharmacy Services, Inc.
- Category
- Drug — Injectable medication
- Hazard
- sterility-failure
- contamination
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Lot: 36-240224
- Exp. 7/16/2023
- 36-242322
- EXP. 7/24/2023
- 36-242445
- Exp. 7/25/2023
- 36-243305
- Exp. 7/27/2023
- 36-243813
- Exp. 7/31/2023
- 36-246166
- 36-246167
- Exp. 8/3/2023
- 36-247670
- Exp. 8/9/2023
- 36-248992
- Exp.8/16/2023
- 36-249468
- Exp. 8/17/2023
- 36-249590
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27